Introduction {#bjs10286-sec-0005}
============

More than 8500 new cases of breast cancer are diagnosed in Sweden each year[1](#bjs10286-bib-0001){ref-type="ref"}. The surgical alternatives are breast‐conserving surgery and mastectomy, which is performed in about 35--50 per cent of patients. The choice of surgical intervention in the breast is based mainly on patient and tumour characteristics, as well as surgeon skills and patient preference.

Mastectomy may be experienced as a mutilating intervention and can, especially in younger women, have negative psychological effects such as reduced self‐esteem, changed body image and sexual problems[2](#bjs10286-bib-0002){ref-type="ref"}. Breast reconstruction may improve body image and quality of life[3](#bjs10286-bib-0003){ref-type="ref"}, [4](#bjs10286-bib-0004){ref-type="ref"}, and can be performed either at primary cancer surgery (immediate breast reconstruction, IBR) or at a later date (secondary or delayed reconstruction, DBR). The breast shape and volume may be recreated using an implant, autologous tissue, or a combination of both. The patient should be made aware that all methods have their inherent advantages and disadvantages. Swedish national guidelines state that any woman scheduled for mastectomy should be offered information about the possibility of breast reconstruction. The same is stated in the UK National Institute for Health and Care Excellence (NICE) guidelines, which point out that this information is independent of locally available options[5](#bjs10286-bib-0005){ref-type="ref"}, [6](#bjs10286-bib-0006){ref-type="ref"}.

The patient--surgeon relationship has evolved from the surgeon‐dominant (paternalistic) model to the informed (consumerist) and shared decision‐making model[7](#bjs10286-bib-0007){ref-type="ref"}, [8](#bjs10286-bib-0008){ref-type="ref"}. The level of patient involvement in this decision‐making process has been shown to influence patient satisfaction and quality of life[9](#bjs10286-bib-0009){ref-type="ref"}. The frequency with which general surgeons discuss breast reconstruction at the time of surgical treatment decision‐making, and the quality of such information, may vary considerably, yet this has an undeniable impact on patients\' choice, postdecision regret and satisfaction[10](#bjs10286-bib-0010){ref-type="ref"}, [11](#bjs10286-bib-0011){ref-type="ref"}, [12](#bjs10286-bib-0012){ref-type="ref"}.

Regional variations in IBR rates are an international problem. In a national audit performed in England, regional rates of immediate reconstruction varied between 9 and 43 per cent, with a national average of 21 per cent[13](#bjs10286-bib-0013){ref-type="ref"}. In Sweden, the proportion of women who underwent IBR per region in 2014 (the year of the most recently reported national audit) lies between 1·7 and 25·4 per cent, with a national average of only 8·7 per cent. IBR rates of individual breast clinics ranged from 0 to 49·5 per cent in that year. Interestingly, the frequency of primary reconstruction was highest in hospitals and regions with the largest proportion of breast‐conserving surgery, suggesting a generally more frequent use of oncoplastic and reconstructive techniques[1](#bjs10286-bib-0001){ref-type="ref"}.

It may be argued that variations in IBR rates are due to regional variations in age, patient preferences, tumour stage, healthcare infrastructure or the use of postoperative radiotherapy. Another hypothesis is that the lack of patient information and involvement in decision‐making before breast cancer surgery may play a significant role. The aim of this study was to analyse the causes of the observed regional variations in IBR rates in Sweden, based on both tumour data and patient‐reported experience of information and decision‐making before surgery.

Methods {#bjs10286-sec-0006}
=======

This study was designed as a cross‐sectional retrospective audit, covering all women with a newly diagnosed primary breast cancer who were registered as having had a mastectomy as the final surgical intervention in Sweden in 2013. Data were extracted from the Swedish National Breast Cancer Registry, which covers 99--100 per cent of all new breast cancer cases. Data on tumour and patient characteristics, diagnostic findings, surgical procedure and treating hospital, nodal status and oncological treatment were requested. Personal identification numbers were then used to obtain postal addresses from the tax authority for the distribution of questionnaires.

All patients alive according to the Population Registry at study initiation in spring 2015 received a postal questionnaire about the preoperative information given regarding reconstructive possibilities and the experience of participation in the decision‐making process before surgery (*Fig. S1*, supporting information). The questionnaire also covered hereditary risks and the patient\'s own desire to have a breast reconstruction. Additional questions regarding the choice of mastectomy instead of breast‐conserving treatment will be covered in an upcoming report. One questionnaire reminder was sent after 3 months to women who had not yet replied. The study was closed on 30 October 2015. The database is managed and protected in accordance with the Swedish Data Protection Act.

A synchronous postal questionnaire was sent to all members of the Swedish Association of Breast Surgery (*Fig. S2*, supporting information). Here, information on breast surgeons\' oncoplastic and reconstructive experience and skills, as well as the availability of oncoplastic and reconstructive services at their own hospital, was requested. Answers were anonymous and could not be linked to specific individuals or institutions.

The study was approved by the Ethics Review Board at Karolinska Institute, Stockholm, in 2014 (2014/2106‐31/1).

Statistical analysis {#bjs10286-sec-0007}
--------------------

Descriptive data are presented as numbers with percentages, or as median (range) values. Comparison of median values for continuous variables in more than two groups was performed using the Kruskal--Wallis test; for two groups, the Mann--Whitney *U* test was employed. χ^2^ or Fisher\'s exact test was used to analyse the distribution of categorical variables between groups.

Univariable and multivariable analysis of the outcome effect of the performance of IBR was performed by binary logistic regression. Results are presented as hazard ratios (HRs) with their respective 95 per cent confidence intervals (c.i.).

All data analysis was performed using SPSS^®^ version 22 (IBM, Armonk, New York, USA). Statistical significance was set at a level of 5 per cent for all analyses.

Results {#bjs10286-sec-0008}
=======

Overall, 2929 women were identified through the Swedish National Breast Cancer Registry as having undergone 2996 mastectomies as the final surgical intervention for newly diagnosed breast cancer in Sweden in the year 2013; thus, 67 women had a bilateral mastectomy. In 412 women (13·8 per cent), breast conservation was attempted primarily and the mastectomy was performed at a second session. Preoperative and postoperative patient and tumour characteristics for women who had IBR and those who did not have IBR are shown in *Table* [1](#bjs10286-tbl-0001){ref-type="table-wrap"}.

###### 

Patient and tumour characteristics for 2996 mastectomies (2929 women)

                                                                                    No immediate reconstruction (*n* = 2726)   Immediate reconstruction (*n* = 270)   *P* [†](#bjs10286-note-0003){ref-type="fn"}
  --------------------------------------------------------------------------------- ------------------------------------------ -------------------------------------- -------------------------------------------------
  Age (years)[\*](#bjs10286-note-0002){ref-type="fn"}                               66 (21--97)                                49 (21--80)                            \< 0·001[‡](#bjs10286-note-0004){ref-type="fn"}
  Preoperative T category                                                                                                                                             \< 0·001
  cTis (*in situ* only)                                                             97 (3·6)                                   46 (17·0)                              
  cT1 (≤ 20 mm)                                                                     988 (36·2)                                 81 (30·0)                              
  cT2 (21--50 mm)                                                                   1065 (39·1)                                67 (24·8)                              
  cT3 (\> 50 mm)                                                                    240 (8·8)                                  21 (7·8)                               
  cT4                                                                               43 (1·6)                                   3 (1·1)                                
  Missing or unknown                                                                293 (10·7)                                 52 (19·3)                              
  Preoperative node status                                                                                                                                            \< 0·001
  Negative                                                                          2214 (81·2)                                250 (92·6)                             
  Positive                                                                          484 (17·8)                                 19 (7·0)                               
  Missing                                                                           28 (1·0)                                   1 (0·4)                                
  Postoperative invasive tumour size (mm)[\*](#bjs10286-note-0002){ref-type="fn"}   22 (1--150)                                17 (1--245)                            \< 0·001[‡](#bjs10286-note-0004){ref-type="fn"}
  Postoperative node status                                                                                                                                           \< 0·001
  Negative                                                                          1478 (54·2)                                188 (69·6)                             
  Positive                                                                          1096 (40·2)                                60 (22·2)                              
  Missing                                                                           152 (5·6)                                  22 (8·1)                               
  Histological subtype                                                                                                                                                0·018
  Ductal                                                                            1877 (68·9)                                151 (55·9)                             
  Lobular                                                                           471 (17·3)                                 17 (6·3)                               
  Other                                                                             140 (5·1)                                  7 (2·6)                                
  Missing                                                                           238 (8·7)                                  95 (35·2)                              
  Presence of multifocality                                                         674 (24·7)                                 47 (17·4)                              0·858
  Nottingham histological grade                                                                                                                                       0·131
  1                                                                                 361 (13·2)                                 34 (12·6)                              
  2                                                                                 1323 (48·5)                                115 (42·6)                             
  3                                                                                 921 (33·8)                                 106 (39·3)                             
  Missing                                                                           121 (4·4)                                  15 (5·6)                               
  Oestrogen receptor status                                                                                                                                           0·406
  Positive                                                                          2107 (77·3)                                165 (61·1)                             
  Negative                                                                          390 (14·3)                                 25 (9·3)                               
  Missing                                                                           229 (8·4)                                  80 (29·6)                              
  Progesterone receptor status                                                                                                                                        0·093
  Positive                                                                          1766 (64·8)                                143 (53·0)                             
  Negative                                                                          719 (26·4)                                 43 (15·9)                              
  Missing                                                                           241 (8·8)                                  84 (31·1)                              
  Her2/neu status                                                                                                                                                     0·915
  Positive                                                                          392 (14·4)                                 27 (10·0)                              
  Negative                                                                          2064 (75·7)                                149 (55·2)                             
  Missing                                                                           270 (9·9)                                  94 (34·8)                              
  Proliferation (Ki‐67)[\*](#bjs10286-note-0002){ref-type="fn"}                     24 (0--100)                                20 (0--95)                             0·019[‡](#bjs10286-note-0004){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise:

values are median (range). One woman with no information on immediate reconstruction was excluded.

χ^2^ or Fisher\'s exact test, except

Mann--Whitney *U* test.

Excluding 23 women who, according to the Population Registry, had died between the operation and initiation of the study, 2906 women were then sent a postal questionnaire regarding their preoperative experience of information and decision‐making. The response rate was 76·3 per cent (2217 of 2906) after one postal reminder.

Immediate breast reconstruction rates {#bjs10286-sec-0009}
-------------------------------------

Overall, IBR was performed in 270 (9·0 per cent) of 2996 mastectomies. The differences in reconstruction rates between regions were marked (*P* \< 0·001) (*Table* [2](#bjs10286-tbl-0002){ref-type="table-wrap"}). To find an explanation for these differences, the distribution of factors increasing the likelihood of postoperative radiotherapy was studied. Actual rates of planned postoperative radiotherapy and age at surgery were also analysed. Even though there were significant differences in preoperative tumour stage, rates of neoadjuvant treatment and the frequency of planned postoperative radiotherapy (as discussed at the postoperative multidisciplinary team meeting), these differences could not explain variations in reconstruction rates. The region with the highest IBR rate (Stockholm/Gotland) also had the highest rate of neoadjuvant therapy and highest percentage of more advanced tumours (cT3--4), whereas the region with the lowest IBR rate (West) had the highest percentage of smaller tumours and the lowest rate of both neoadjuvant therapy and postoperative radiotherapy. Median patient age did not differ between regions.

###### 

Immediate reconstruction rates and preoperative patient and tumour characteristics for 2996 mastectomies, in each Swedish healthcare region

                                                                              Swedish healthcare region                                                                         
  --------------------------------------------------------------------------- --------------------------- ------------- ------------- ------------- ------------- ------------- -----------------------------------------------
  Immediate breast reconstruction rate                                        10 (4·7)                    151 (26·4)    30 (4·8)      23 (6·1)      39 (6·2)      17 (3·0)      \< 0·001
  Preoperative T category[†](#bjs10286-note-0007){ref-type="fn"}                                                                                                                \< 0·001
  cT1                                                                         85 (39·9)                   145 (25·4)    248 (39·4)    138 (36·4)    205 (32·5)    248 (43·2)    
  cT2                                                                         71 (33·3)                   227 (39·8)    226 (35·9)    127 (33·5)    258 (41·0)    223 (38·9)    
  cT3                                                                         18 (8·5)                    72 (12·6)     34 (5·4)      33 (8·7)      69 (11·0)     35 (6·1)      
  cT4                                                                         9 (4·2)                     11 (1·9)      6 (1·0)       4 (1·1)       11 (1·7)      5 (0·9)       
  *In situ* only                                                              8 (3·8)                     27 (4·7)      49 (7·8)      6 (1·6)       25 (4·0)      28 (4·9)      
  Unknown or missing                                                          22 (10·3)                   89 (15·6)     66 (10·5)     71 (18·7)     62 (9·8)      35 (6·1)      
  Preoperative N category[†](#bjs10286-note-0007){ref-type="fn"}                                                                                                                0·082
  cN0                                                                         170 (79·8)                  480 (84·1)    513 (81·6)    316 (83·4)    523 (83·0)    462 (80·5)    
  cN1                                                                         31 (14·6)                   84 (14·7)     96 (15·3)     60 (15·8)     92 (14·6)     106 (18·5)    
  cN2                                                                         5 (2·3)                     3 (0·5)       7 (1·1)       0 (0)         7 (1·1)       1 (0·2)       
  cN3                                                                         0 (0)                       2 (0·3)       3 (0·5)       0 (0)         4 (0·6)       2 (0·3)       
  Missing                                                                     7 (3·3)                     2 (0·3)       10 (1·6)      3 (0·8)       4 (0·6)       3 (0·5)       
  Neoadjuvant therapy[‡](#bjs10286-note-0008){ref-type="fn"}                  26 (12·2)                   94 (16·5)     60 (9·5)      41 (10·8)     32 (5·1)      26 (4·5)      \< 0·001
  Postoperative radiotherapy planned[§](#bjs10286-note-0009){ref-type="fn"}   91 (42·7)                   279 (48·9)    201 (32·0)    174 (45·9)    274 (43·5)    176 (30·7)    \< 0·001
  Age at surgery (years)[\*](#bjs10286-note-0006){ref-type="fn"}              65 (28--93)                 62 (21--96)   65 (26--94)   63 (21--93)   65 (24--94)   66 (26--97)   0·052[\#](#bjs10286-note-0011){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are median (range) for individual patients per region.

Based on clinical examination and imaging modalities, following the TNM classification system.

Includes both endocrine and cytostatic treatments.

As recommended by the multidisciplinary team; includes both local and locoregional radiotherapy.

χ^2^ test, except

Kruskal--Wallis test.

Factors affecting the likelihood of immediate breast reconstruction {#bjs10286-sec-0010}
-------------------------------------------------------------------

Independent predictors of undergoing IBR were surgery in the Stockholm/Gotland region, undergoing operation at a hospital with in‐house plastic surgery services, and having a preoperative working diagnosis of *in situ* disease only (*Table* [3](#bjs10286-tbl-0003){ref-type="table-wrap"}). Clinically involved lymph nodes and age above 60 years decreased the likelihood of IBR. Women who reported no participation in the preoperative decision‐making process and those not informed about immediate reconstructive options had a low likelihood of IBR.

###### 

Univariable and multivariable binary logistic regression analysis of factors, with performance of immediate breast reconstruction as the binary outcome effect measure

                                                                      Univariable analysis   Multivariable analysis                        
  ------------------------------------------------------------------- ---------------------- ------------------------ -------------------- ----------
  Preoperative tumour size (TNM)                                                                                                           
  cT1 (≤ 20 mm)                                                       1·00 (reference)                                                     
  cT2 (21--50 mm)                                                     0·77 (0·55, 1·07)      0·123                    0·68 (0·41, 1·15)    0·156
  cT3 (\> 50 mm)                                                      1·07 (0·65, 1·76)      0·802                    1·01 (0·46, 2·19)    0·983
  cT4                                                                 0·85 (0·26, 2·80)      0·790                    0·92 (0·08, 10·43)   0·947
  *In situ* only                                                      5·78 (3·81, 8·77)      \< 0·001                 3·21 (1·69, 6·10)    \< 0·001
  Unknown primary                                                     2·22 (1·52, 3·24)      \< 0·001                 1·68 (0·95, 2·98)    0·074
  Preoperative N category                                                                                                                  
  cN−                                                                 1·00 (reference)                                                     
  cN+                                                                 0·35 (0·22, 0·56)      \< 0·001                 0·31 (0·13, 0·73)    0·007
  Age (years)                                                                                                                              
  \< 41                                                               1·00 (reference)                                                     
  41--50                                                              0·82 (0·55, 1·21)      0·322                    0·93 (0·46, 1·88)    0·848
  51--60                                                              0·50 (0·33, 0·75)      0·001                    0·58 (0·28, 1·17)    0·129
  61--70                                                              0·13 (0·08, 0·22)      \< 0·001                 0·16 (0·07, 0·36)    \< 0·001
  \> 70                                                               0·01 (0·01, 0·04)      \< 0·001                 0·02 (0·00, 0·08)    \< 0·001
  Swedish healthcare region                                                                                                                
  North                                                               1·00 (reference)                                                     
  Stockholm/Gotland                                                   7·30 (3·77, 14·14)     \< 0·001                 4·91 (1·85, 13·06)   0·001
  South                                                               1·02 (0·49, 2·13)      0·954                    1·07 (0·40, 2·88)    0·885
  South‐east                                                          1·31 (0·61, 2·81)      0·486                    1·20 (0·42, 3·43)    0·738
  Uppsala/Örebro                                                      1·34 (0·66, 2·73)      0·421                    1·05 (0·38, 2·95)    0·919
  West                                                                0·62 (0·62, 1·38)      0·239                    0·60 (0·19, 1·90)    0·381
  Neoadjuvant treatment                                                                                                                    
  No                                                                  1·00 (reference)                                                     
  Yes                                                                 0·77 (0·48, 1·24)      0·289                    0·72 (0·30, 1·77)    0·480
  Hereditary factors                                                                                                                       
  No                                                                  1·00 (reference)                                                     
  Yes                                                                 1·35 (0·92, 1·99)      0·121                    1·33 (0·80, 2·22)    0·274
  Patient participation in decision‐making regarding reconstruction                                                                        
  Yes                                                                 1·00 (reference)                                                     
  No                                                                  0·07 (0·04, 0·14)      \< 0·001                 0·41 (0·18, 0·90)    0·026
  Patient informed about immediate reconstructive options                                                                                  
  Yes                                                                 1·00 (reference)                                                     
  No                                                                  0·05 (0·25, 0·11)      \< 0·001                 0·10 (0·05, 0·21)    \< 0·001
  In‐house plastic surgery services available at operating hospital                                                                        
  Yes                                                                 1·00 (reference)                                                     
  No                                                                  0·19 (0·13, 0·27)      \< 0·001                 0·39 (0·23, 0·66)    \< 0·001

Values in parentheses are 95 per cent confidence intervals.

The in‐house availability of plastic surgery services was distributed unevenly between regions: although 95·3 per cent of all patients in the Stockholm/Gotland region had surgery in units with in‐house plastic surgery services, the rate ranged between 30·0 and 57·8 per cent for the other regions. As evident from *Table* [3](#bjs10286-tbl-0003){ref-type="table-wrap"}, however, the availability of in‐house plastic surgery services did not suffice to explain regional differences, but did increase the chance of being informed about IBR options (HR 0.74, 95 per cent c.i. 0.62 to 0.87).

In‐house plastic surgery services may be provided by an institution\'s own department of plastic surgery, by plastic surgeons employed by the department of general surgery or by consultation services only. Interestingly, IBR rates were significantly higher in regional hospitals with a plastic surgeon available but without a department of plastic surgery than in university hospitals with their own departments of plastic surgery (17·2 *versus* 11·5 per cent; *P* \< 0·001). Where there was no plastic surgery service, the IBR rate decreased to 3·0 per cent (41 of 1365).

Patient information and participation in the decision‐making process {#bjs10286-sec-0011}
--------------------------------------------------------------------

Of all responding women who did not have IBR, 33·7 per cent (657 of 1947) reported not wanting any breast reconstruction, and the proportion of women wishing to wait for breast reconstruction until a later date was only 8·0 per cent (155 of 1947).

In a second step, only those women with a low likelihood of relative contraindications for IBR were selected (clinically node‐negative patients with small tumours (cT1), *in situ* disease only (cTis) or no clinical signs of primary tumour (cT0)). To take age into consideration, only women aged up to 65 years were then selected from this 'low tumour burden' group. Patient participation and information still varied extensively between Swedish healthcare regions, further contradicting the assumption that younger women with a low probability of postoperative radiotherapy would receive sufficient information on IBR (*Table* [4](#bjs10286-tbl-0004){ref-type="table-wrap"}). Even though patient information regarding DBR also varied significantly in the low tumour burden group, the percentage of patients receiving information on DBR was generally higher.

###### 

Preoperative patient‐reported perception of information about breast reconstruction and involvement in treatment decision, in each Swedish healthcare region

                                                                                                                   Swedish healthcare region                                                                   
  ---------------------------------------------------------------------------------------------------------------- --------------------------- ------------ ------------ ----------- ------------ ------------ ---------
  Any age                                                                                                                                                                                                      
  Did you receive information about the possibility of immediate reconstruction of the breast?                                                                                                                 
  Group 1                                                                                                          36 (45·6)                   123 (67·2)   120 (48·4)   64 (41·0)   69 (35·8)    63 (31·0)    \<0·001
  Group 2                                                                                                          16 (25·0)                   130 (56·3)   60 (27·8)    43 (33·6)   68 (26·4)    53 (24·8)    \<0·001
  Did you receive information about the possibility of delayed reconstruction of the breast in a second setting?                                                                                               
  Group 1                                                                                                          47 (59·5)                   127 (67·9)   160 (65·3)   91 (57·6)   122 (62·6)   127 (62·6)   0·008
  Group 2                                                                                                          33 (49·3)                   157 (67·7)   120 (55·3)   74 (57·4)   135 (52·5)   130 (60·7)   0·425
  Did you feel involved in the decision‐making process whether or not to perform breast reconstruction?                                                                                                        
  Group 1                                                                                                          52 (72·2)                   136 (75·1)   156 (66·1)   88 (59·9)   104 (58·1)   114 (61·3)   0·005
  Group 2                                                                                                          33 (53·2)                   164 (74·5)   101 (50·0)   61 (54·5)   133 (59·1)   108 (55·1)   \<0·001
  Age up to 65 years                                                                                                                                                                                           
  Did you receive information about the possibility of immediate reconstruction of the breast?                                                                                                                 
  Group 1                                                                                                          28 (58·3)                   95 (83·3)    84 (59·6)    48 (56·5)   55 (47·8)    35 (34·3)    \<0·001
  Group 2                                                                                                          12 (36·4)                   98 (73·7)    40 (35·7)    34 (42·5)   45 (36·3)    29 (27·1)    \<0·001
  Did you receive information about the possibility of delayed reconstruction of the breast in a second setting?                                                                                               
  Group 1                                                                                                          40 (83·3)                   97 (84·3)    118 (84·9)   70 (81·4)   102 (87·2)   85 (82·5)    0·903
  Group 2                                                                                                          26 (74·3)                   119 (88·8)   91 (81·3)    66 (81·5)   99 (80·5)    88 (81·5)    0·314
  Did you feel involved in the decision‐making process whether or not to perform breast reconstruction?                                                                                                        
  Group 1                                                                                                          36 (76·6)                   94 (83·9)    100 (72·5)   57 (68·7)   78 (68·4)    57 (62·6)    \<0·001
  Group 2                                                                                                          17 (53·1)                   112 (85·5)   58 (53·2)    46 (62·2)   81 (69·2)    62 (61·4)    0·018

Values are numbers of women who answered 'Yes' or 'Yes, but not enough' to each question, with percentages in parentheses. Group 1 (low tumour burden) consisted of women with clinically node‐negative cT1, cTis (*in situ*) or cT0 tumours. Group 2 (higher tumour burden) consisted of all remaining women.

χ^2^ test.

Education and skill level in reconstructive techniques among breast surgeons {#bjs10286-sec-0012}
----------------------------------------------------------------------------

The response rate of surgeons registered as members of the Swedish Association of Breast Surgery was 60·3 per cent (91 of 151). Five surgeons reported they had either retired or stopped working with patients with breast cancer. Thus, the number of completed questionnaires was 86. All respondents had completed their training in general surgery, and eight also had completed plastic surgery training (9 per cent). The majority of respondents were senior surgeons with more than 5 years as a consultant (72 of 86; 84 per cent), and with breast surgery representing more than 50 per cent of their daily clinical activities (64 of 86; 74 per cent). A majority (76 per cent) reported IBR to be available at their own hospital, and a further 17 per cent could refer the patient to a different unit. The availability of IBR was no different between university and regional hospitals (*P* = 0·330). Less than half of respondents could perform an IBR independently (36 of 86; 42 per cent). Median age was 55 (range 34--71) years, and the distribution between regional/county hospitals and university hospitals was even. A large majority (81 per cent) wished to gain more training in oncoplastic breast surgery. As questionnaires were returned anonymously, it was not possible to link data of individual surgeons to their respective units and regions.

Discussion {#bjs10286-sec-0013}
==========

In the present analysis, the marked differences in IBR rates in the six Swedish healthcare regions were not explained by differences in disease characteristics or age distribution. Although more advanced disease and other established risk factors for an inferior IBR outcome varied between healthcare regions, and predictably had an impact on IBR rates in all regions, these factors could not explain regional variations in breast reconstruction rates as they did not follow the same pattern as the latter. Instead, significant deficits in patient information and participation in decision‐making were found that were congruent with differences in immediate reconstruction rates. These deficits still persisted when studying a selected group of younger, low‐risk women. Actual rates of DBR are unknown, but patient information regarding DBR was generally more frequent than that regarding IBR.

Some factors that are agreed to pose a risk to surgical and cosmetic outcome after IBR, such as smoking or obesity, could not be assessed in the present analysis, whereas others, such as the risk of postoperative radiotherapy, were studied in detail. It is important to remember that the decision to perform IBR or not is most commonly taken before obtaining complete knowledge of the disease extent and biology, and thus prior to knowledge of postoperative treatment. Therefore, the analysis was based on clinical factors known to the surgeon before operation. It is also important to remember that the discussion whether or not to offer IBR lies in the hands of the breast surgeon scheduling the patient for surgery; in institutions where plastic surgeons rather than breast surgeons perform reconstructive surgery, information on reconstructive options has to be delivered by the breast surgeon, who may then confer with the plastic surgeon in case the patient opts for IBR or requires more information on different reconstructive options. Thus, the lack of patient information lies with the breast surgeon, and it may be hypothesized that surgeons trained in reconstructive breast surgery are more likely to inform about this surgical alternative than those who are not. Supporting this fact is the notion that rates of patient information and patient participation regarding IBR were significantly higher in the Stockholm region, where breast and plastic surgeons both independently and in collaboration routinely perform IBR[14](#bjs10286-bib-0014){ref-type="ref"}.

The lack of in‐house plastic surgery services had a significant impact on IBR performance and also affected the rate of patient information negatively. This problem may be met by two principal proposals: the employment of plastic surgeons at non‐university hospitals, which here was shown to result in higher IBR rates; and the oncoplastic and reconstructive training of breast surgeons, as called for by international consensus[15](#bjs10286-bib-0015){ref-type="ref"}. An increased collaboration between breast and plastic surgeons is crucial to address these issues[16](#bjs10286-bib-0016){ref-type="ref"}. Clearly, reconstructive resources would need to increase in order to meet an increasing demand for IBR most likely resulting from sufficient patient information.

Naturally, offering more women reconstructive options increases breast reconstruction rates[17](#bjs10286-bib-0017){ref-type="ref"}. It is tempting to think that a patient with risk factors for an inferior IBR outcome would not need to receive information on the different reconstructive options available, especially not those that the surgeon does not favour. A large number of publications are available on the surgical outcomes and cosmetic results after IBR, showing for example the negative effects of postmastectomy radiotherapy (PMRT) on reconstructive outcomes[18](#bjs10286-bib-0018){ref-type="ref"}, [19](#bjs10286-bib-0019){ref-type="ref"}. Few of these, however, report the patients\' own attitudes towards IBR. It is therefore most noteworthy that, when presented with the choice of IBR or DBR *versus* no breast reconstruction, and with awareness of the potentially negative effects of PMRT, the majority women still choose IBR[20](#bjs10286-bib-0020){ref-type="ref"}, [21](#bjs10286-bib-0021){ref-type="ref"}, would choose it again[22](#bjs10286-bib-0022){ref-type="ref"}, and would recommend it to others[23](#bjs10286-bib-0023){ref-type="ref"}. This, in combination with the fact that there is still only sparse evidence favouring either IBR or DBR[24](#bjs10286-bib-0024){ref-type="ref"}, should encourage the surgeon to discuss advantages and disadvantages of available options with the woman to offer her an evidence base on which to decide on her individual choice of breast cancer surgery.

Patient choices are complex and, although some women might focus on the aesthetic outcome of a reconstruction, others focus on practicalities, risk of complications, scarring and extent of the surgical procedure[20](#bjs10286-bib-0020){ref-type="ref"}, [21](#bjs10286-bib-0021){ref-type="ref"}, [25](#bjs10286-bib-0025){ref-type="ref"}, [26](#bjs10286-bib-0026){ref-type="ref"}. Patient involvement in the decision‐making process is known to increase levels of satisfaction and quality of life, and a 'paternalistic' level of decision‐making was clearly inferior to 'shared' and 'informed' levels[9](#bjs10286-bib-0009){ref-type="ref"}. This is true also for the elderly, who participate equally in the decision‐making process[27](#bjs10286-bib-0027){ref-type="ref"}; in this special subgroup, cosmetic and patient satisfaction outcomes after breast reconstruction are as good as those achieved in younger patients, yet older women are far less likely to be offered these techniques[28](#bjs10286-bib-0028){ref-type="ref"}.

The present results need to be interpreted in the light of some limitations. First, retrospective studies are subject to recall bias[29](#bjs10286-bib-0029){ref-type="ref"}, and the study included women who were surveyed up to 2 years after their surgical treatment. Recall bias is often directional, such that patients feel more informed than their knowledge level actually suggests; in other cases, recall bias may be an expression of recall deficit, which may be lacking direction[30](#bjs10286-bib-0030){ref-type="ref"}. Feeling well informed may also be dependent on socioeconomic factors[31](#bjs10286-bib-0031){ref-type="ref"}. Second, this study did not have access to socioeconomic and co‐morbidity data, such as income, educational level, bodyweight, smoking and other concurrent diseases, that may influence the decision‐making process for breast reconstruction. There is no evidence, however, that these factors would be sufficiently divergent in the studied Swedish healthcare regions to explain the observed differences: each region has its own university healthcare and combines urban and rural areas. Although counties and communes do diverge in terms of income and education[32](#bjs10286-bib-0032){ref-type="ref"}, the larger healthcare regions used should not. As there are no published reports comparing healthcare regions regarding socioeconomic factors, raw data will be obtained for the upcoming analysis of rates of breast‐conserving surgery and patient information.

Regional differences in IBR rates were thus caused mainly by a lack of patient information and participation in the decision‐making process, as well as a lack of in‐house plastic surgery services. Older women were significantly less likely to receive information on IBR, and age was an independent predictor of not receiving IBR. Even though there are factors known negatively to affect the outcomes of IBR, informed decision‐making and the availability of individual choices positively affect quality of life and levels of satisfaction, underlining the need for evidence‐based, shared patient education in the face of mastectomy planning. To reduce regional differences in patient information and IBR rates, a focus should be put on oncoplastic and reconstructive training as well as improved collaboration between breast and plastic surgeons.
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